Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.

ABSTRACT:

SUBMITTER: Wan EYF 

PROVIDER: S-EPMC9943556 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature